Christoph Lange

Dec 26, 2024 | journalofinfection.com | Marit Neumann |Maja Reimann |Dumitru Chesov |Cristina Popa |Antonela Dragomir |Oana Popescu | +7 more

KeywordsDrug-resistant tuberculosispulmonary tuberculosisdiagnostic evaluationmolecular bacterial load assay (MBLA)IntroductionTuberculosis (TB) is a leading cause of morbidity and mortality world-wide.

Dec 10, 2024 | publications.ersnet.org | Traian Constantin Panciu |Christoph Lange |Raquel Duarte |Mairi McClean

IntroductionTuberculosis (TB) is a persistent global health challenge, with 7.5 million new diagnoses and an estimated incidence of 10.6 million cases in 2022 [1]. At present, achieving the World Health Organization (WHO) End-TB Strategy's ambitious aims for a 95% decrease in TB-related deaths and a 90% decline in TB incidence rate by 2035 appears unrealistic [2]. The status quo of TB control methods is fraught with challenges.

Dec 10, 2024 | publications.ersnet.org | Jodie A. Schildkraut |Niklas Köhler |Christoph Lange |Raquel Duarte

IntroductionTuberculosis (TB) continues to be one of the deadliest infectious diseases worldwide, with 10.6 million individuals developing the disease and ∼1.3 million deaths in 2022 [1]. The limitations of conventional diagnostic methods (e.g. sputum smear microscopy, PCR and culture), such as their slow turnaround times, lack of sensitivity in certain cohorts and technical challenges, have been well recognised [2, 3].

Sep 1, 2024 | openres.ersjournals.com | Michael R Loebinger |Stefano Aliberti |Charles S. Haworth |Christoph Lange

FootnotesProvenance: Submitted article, peer reviewed. Authors contributions: M.R. Loebinger and J. van Ingen conceived and developed the surveys for all rounds of voting. All panellists and authors discussed and shaped the content for voting Rounds 2 and 3. All authors discussed the content of the manuscript from the face-to-face meetings; they also conceived and developed the outline and all manuscript drafts. All authors critically reviewed and approved the final draft for submission.

Sep 1, 2023 | breathe.ersjournals.com | Francesca Saluzzo |Victor Abiola Adepoju |Raquel Duarte |Christoph Lange

Overview of studies supporting all-oral shorter regimens for DR-TBTo provide a full overview of the trial results, the number and percentage of grade 3 or higher adverse events for each of the four trials are described in table 2.